1. C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice.
- Author
-
Zwijnenburg PJ, van der Poll T, Florquin S, Polfliet MM, van den Berg TK, Dijkstra CD, Roord JJ, Hack CE, and van Furth AM
- Subjects
- Animals, Brain immunology, Brain pathology, Brain Chemistry, Cerebrospinal Fluid microbiology, Chemokines analysis, Colony Count, Microbial, Complement Activation, Complement C1 Inhibitor Protein administration & dosage, Complement Pathway, Classical, Cytokines analysis, Disease Models, Animal, Humans, Macrophage-1 Antigen biosynthesis, Male, Meninges pathology, Meningitis, Pneumococcal microbiology, Mice, Mice, Inbred C57BL, Rats, Rats, Wistar, Streptococcus pneumoniae isolation & purification, Complement C1 antagonists & inhibitors, Complement C1 Inhibitor Protein pharmacology, Meningitis, Pneumococcal immunology, Meningitis, Pneumococcal pathology
- Abstract
In spite of antibiotic treatment, pneumococcal meningitis continues to be associated with significant morbidity and mortality. The complement system is a key component of innate immunity against invading pathogens. However, activation of complement is also involved in tissue damage, and complement inhibition by C1 inhibitor (C1-inh) is beneficial in animal models of endotoxemia and sepsis. In the present study, we demonstrate classical pathway complement activation during pneumococcal meningitis in rats. We also evaluate the effect of C1-inh treatment on clinical illness, bacterial clearance, and inflammatory responses in rats and mice with pneumococcal meningitis. C1-inh treatment was associated with reduced clinical illness, a less-pronounced inflammatory infiltrate around the meninges, and lower brain levels of proinflammatory cytokines and chemokines. C1-inh treatment increased bacterial clearance, possibly through an up-regulation of CR3. Hence, C1-inh may be a useful agent in the treatment of pneumococcal meningitis.
- Published
- 2007
- Full Text
- View/download PDF